247 related articles for article (PubMed ID: 12954498)
21. Treating prostate cancer. Part V: androgen deprivation and chemotherapy.
Harv Mens Health Watch; 1999 Dec; 4(5):5-8. PubMed ID: 10564905
[No Abstract] [Full Text] [Related]
22. Reimbursement policy and androgen-deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF; Gilbert SM
N Engl J Med; 2010 Nov; 363(19):1822-32. PubMed ID: 21047226
[TBL] [Abstract][Full Text] [Related]
23. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
24. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
Kittai AS; Blank J; Graff JN
Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
[TBL] [Abstract][Full Text] [Related]
25. Subcapsular orchiectomy versus total orchiectomy and LHRH analogue in the treatment of hormone-sensitive metastatic prostate cancer: a different perspective in evaluation of the psychosocial effects.
Selvi I; Basar H
Support Care Cancer; 2020 Sep; 28(9):4313-4326. PubMed ID: 31912363
[TBL] [Abstract][Full Text] [Related]
26. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
27. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
[TBL] [Abstract][Full Text] [Related]
28. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
Greiman AK; Keane TE
Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
[TBL] [Abstract][Full Text] [Related]
29. Endocrine therapy for prostate cancer.
Damber JE
Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
[TBL] [Abstract][Full Text] [Related]
30. Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
Liu R; Zhou J; Xia S; Li T
Urol Int; 2020; 104(3-4):214-221. PubMed ID: 31747673
[TBL] [Abstract][Full Text] [Related]
31. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
[TBL] [Abstract][Full Text] [Related]
32. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
Akaza H
Cancer Sci; 2011 Jan; 102(1):51-6. PubMed ID: 21091846
[TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
34. Agonists of luteinizing hormone-releasing hormone in prostate cancer.
Rick FG; Block NL; Schally AV
Expert Opin Pharmacother; 2013 Nov; 14(16):2237-47. PubMed ID: 23984804
[TBL] [Abstract][Full Text] [Related]
35. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
Merseburger AS; Sedding D; Hüter K
Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
[TBL] [Abstract][Full Text] [Related]
36. Controversies surrounding androgen deprivation for prostate cancer.
Patterson SG; Balducci L; Pow-Sang JM
Cancer Control; 2002; 9(4):315-25. PubMed ID: 12228757
[TBL] [Abstract][Full Text] [Related]
37. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
38. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
39. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
40. [Hormone therapy in prostate cancer: clinical results].
Morote-Robles J
Rev Esp Fisiol; 1990 Mar; 46(1):59-62. PubMed ID: 1697693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]